Copyright
©The Author(s) 2022.
World J Gastroenterol. Jun 21, 2022; 28(23): 2582-2596
Published online Jun 21, 2022. doi: 10.3748/wjg.v28.i23.2582
Published online Jun 21, 2022. doi: 10.3748/wjg.v28.i23.2582
Figure 2 Incremental gain analysis of sustained endoscopic remission rate in relation to infliximab trough level at week 14 and week 54.
- Citation: Cao WT, Huang R, Liu S, Fan YH, Xu MS, Xu Y, Ni H. Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn’s disease under infliximab therapy. World J Gastroenterol 2022; 28(23): 2582-2596
- URL: https://www.wjgnet.com/1007-9327/full/v28/i23/2582.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i23.2582